Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Saved in:

Bibliographic Details
Title:	Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
Authors:	Ching THW; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Amoroso L; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Bohner C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., D'Amico E; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Eilbott J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Entezar T; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Fitzpatrick M; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Fram G; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Grazioplene R; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Hokanson J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Kichuk SA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Martins B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Patel P; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Schaer H; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Shnayder S; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Witherow C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States., Pittenger C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Department of Psychology, Yale University, New Haven, CT, United States.; Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States.; Child Study Center, Yale University School of Medicine, New Haven, CT, United States., Kelmendi B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Source:	Frontiers in psychiatry [Front Psychiatry] 2024 Jan 09; Vol. 14, pp. 1278823. Date of Electronic Publication: 2024 Jan 09 (Print Publication: 2023).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-0640
DOI:	10.3389/fpsyt.2023.1278823